Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:54 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 8,606 matching trials from the live ClinicalTrials.gov search.
Filters: Indianapolis, Indiana Clear all
Recruiting Phase 3 Interventional

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT07318558
View directory record Official record
Conditions
Ovarian Neoplasms, Ovarian Cancer
Interventions
Sacituzumab tirumotecan, Bevacizumab, Rescue Medications
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
27
States / cities
Birmingham, Alabama • Walnut Creek, California • Miami Beach, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 2, 2026, 9:54 AM EST
Completed Phase 2 Interventional

Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants

NCT00349726
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol higher volume, Placebo lower volume, Placebo higher volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
3 Days to 6 Days
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
New Haven, Connecticut • Indianapolis, Indiana • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Nov 2, 2026, 9:54 AM EST
Completed Phase 2 Interventional Results available

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

NCT02452476
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
CHF5633, Poractant alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Nov 2, 2026, 9:54 AM EST
Completed Phase 2 Interventional Results available

Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

NCT00189540
View directory record Official record
Conditions
Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
Interventions
HGF plasmid, Placebo
Genetic
Lead sponsor
AnGes USA, Inc.
Industry
Eligibility
40 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Pensacola, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Nov 2, 2026, 9:54 AM EST
Recruiting Not applicable Interventional

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

NCT06423430
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Sham-stimulation, Active-stimulation
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
22 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 9:54 AM EST
Recruiting Phase 1Phase 2 Interventional

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

NCT05562830
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Zilovertamab vedotin, Pembrolizumab, MK-3120
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 2, 2026, 9:54 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

NCT01456936
View directory record Official record
Conditions
Smoking Cessation
Interventions
Placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
8,144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
77
States / cities
Mobile, Alabama • Phoenix, Arizona • Encino, California + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2016 · Synced Nov 2, 2026, 9:54 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

Clinical Outcomes in Patients Treated With SternaLock Blu

NCT03709693
View directory record Official record
Conditions
Cardiac Surgical Procedures, Coronary Artery Disease, Heart Valve Diseases
Interventions
SternaLock Blu
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years to 100 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Indianapolis, Indiana • Kansas City, Missouri • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Nov 2, 2026, 9:54 AM EST
Completed Phase 2 Interventional

Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease

NCT00325728
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
55 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
72
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Nov 2, 2026, 9:54 AM EST
Recruiting Phase 3 Interventional

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

NCT07387367
View directory record Official record
Conditions
Adenovirus Infections
Interventions
cidofovir, Brincidofovir
Drug
Lead sponsor
SymBio Pharmaceuticals
Industry
Eligibility
2 Months and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
32
States / cities
Phoenix, Arizona • Duarte, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 2, 2026, 9:54 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607800
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
47
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Nov 2, 2026, 9:54 AM EST
Terminated Phase 1 Interventional

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

NCT01088763
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Gonadotroph Adenoma, Pituitary Basophilic Adenoma, Pituitary Chromophobe Adenoma, Pituitary Eosinophilic Adenoma, Prolactin Secreting Adenoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Pituitary Tumor, Recurrent/Refractory Childhood Hodgkin Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, TSH Secreting Adenoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study, dexamethasone
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2014 · Synced Nov 2, 2026, 9:54 AM EST
Completed Not applicable Interventional Results available

Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra

NCT00636987
View directory record Official record
Conditions
Aortic Valve Insufficiency, Aortic Valve Regurgitation, Aortic Valve Stenosis, Aortic Valve Incompetence, Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Stenosis, Mitral Valve Incompetence
Interventions
Biocor and Biocor Supra valves
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Evansville, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Nov 2, 2026, 9:54 AM EST
Recruiting Phase 3 Interventional

Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

NCT05646316
View directory record Official record
Conditions
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biospecimen Collection, Diagnostic Imaging Testing, Excisional Biopsy, Indocyanine Green Solution, Minimally Invasive Surgery, Pelvic Lymphadenectomy, Questionnaire Administration, Sentinel Lymph Node Mapping
Procedure · Drug · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
55
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Deerfield Beach, Florida + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 2, 2026, 9:54 AM EST
Completed Not applicable Interventional

Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia

NCT02060630
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Open surgical revascularization, Endovascular revascularization
Procedure · Device
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
1,843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Nov 2, 2026, 9:54 AM EST
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

NCT00336492
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
infliximab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Nov 2, 2026, 9:54 AM EST
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial

NCT05390411
View directory record Official record
Conditions
Implementation Science, Heart Transplant, Decision Making
Interventions
SOCIAL HF
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
1,463 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Nov 2, 2026, 9:54 AM EST
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

NCT05704309
View directory record Official record
Conditions
Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia, PreDiabetes
Interventions
Not listed
Lead sponsor
Marinella Temprosa
Other
Eligibility
Not listed
Enrollment
1,976 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Alhambra, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Nov 2, 2026, 9:54 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

NCT03631732
View directory record Official record
Conditions
HIV-1 Infection
Interventions
B/F/TAF, NRTIs, Third Agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
82
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Nov 2, 2026, 9:54 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

NCT02540993
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5,734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
176
States / cities
Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Nov 2, 2026, 9:54 AM EST
Recruiting No phase listed Observational

Project: Every Child for Younger Patients With Cancer

NCT02402244
View directory record Official record
Conditions
Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Kidney Neoplasm, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Desmoid Fibromatosis, Ganglioneuroma, Lymphoproliferative Disorder, Malignant Neoplasm, Malignant Solid Neoplasm, Melanocytic Neoplasm, Myeloproliferative Neoplasm, Neoplasm of Uncertain Malignant Potential, Neuroendocrine Neoplasm, Stromal Neoplasm
Interventions
Cytology Specimen Collection Procedure, Medical Chart Review
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
75,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
246
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 177 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 2, 2026, 9:54 AM EST
Active, not recruiting Not applicable Interventional

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

NCT01872975
View directory record Official record
Conditions
Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
regional nodal XRT, chestwall XRT, WBI
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
1,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
489
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 356 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Nov 2, 2026, 9:54 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Understanding and Predicting Breast Cancer Events After Treatment

NCT02791581
View directory record Official record
Conditions
Breast Cancer
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
403 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2032
U.S. locations
66
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 2, 2026, 9:54 AM EST
Recruiting Phase 3 Interventional

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892
View directory record Official record
Conditions
Bronchiectasis
Interventions
BI 1291583, Placebo matching BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
1,755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 2, 2026, 9:54 AM EST